These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38359700)

  • 21. ZNF281 Promotes Colon Fibroblast Activation in TGFβ1-Induced Gut Fibrosis.
    Laudadio I; Bastianelli A; Fulci V; Carissimi C; Colantoni E; Palone F; Vitali R; Lorefice E; Cucchiara S; Negroni A; Stronati L
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease.
    Lovisa S; Genovese G; Danese S
    J Crohns Colitis; 2019 Apr; 13(5):659-668. PubMed ID: 30520951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis.
    Geboes KP; Cabooter L; Geboes K
    Acta Gastroenterol Belg; 2000; 63(4):371-6. PubMed ID: 11233520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of fibrosis and stricture formation in Crohn's disease.
    Alfredsson J; Wick MJ
    Scand J Immunol; 2020 Dec; 92(6):e12990. PubMed ID: 33119150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide.
    Li C; Flynn RS; Grider JR; Murthy KS; Kellum JM; Akbari H; Kuemmerle JF
    Inflamm Bowel Dis; 2013 Dec; 19(13):2829-39. PubMed ID: 24051933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.
    Santacroce G; Lenti MV; Di Sabatino A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bowel stiffness associated with histopathologic scoring of stenosis in patients with Crohn's disease.
    Zhao J; Liao D; Wilkens R; Krogh K; Glerup H; Gregersen H
    Acta Biomater; 2021 Aug; 130():332-342. PubMed ID: 34119715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.
    Jacob N; Jacobs JP; Kumagai K; Ha CWY; Kanazawa Y; Lagishetty V; Altmayer K; Hamill AM; Von Arx A; Sartor RB; Devkota S; Braun J; Michelsen KS; Targan SR; Shih DQ
    Mucosal Immunol; 2018 Sep; 11(5):1466-1476. PubMed ID: 29988118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating the role of heat shock protein 47 in fibrosis in Crohn's disease.
    Kurumi H; Takata T; Kanda T; Sugihara T; Kakugawa T; Yokota SI; Morisaki T; Akashi T; Isomoto H
    Sci Rep; 2022 Jun; 12(1):10966. PubMed ID: 35768471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elafin Reverses Intestinal Fibrosis by Inhibiting Cathepsin S-Mediated Protease-Activated Receptor 2.
    Xie Y; Fontenot L; Chupina Estrada A; Nelson B; Wang J; Shih DQ; Ho W; Mattai SA; Rieder F; Jensen DD; Bunnett NW; Koon HW
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):841-876. PubMed ID: 35840034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and Molecular Mediators of Intestinal Fibrosis.
    Lawrance IC; Rogler G; Bamias G; Breynaert C; Florholmen J; Pellino G; Reif S; Speca S; Latella G
    J Crohns Colitis; 2017 Dec; 11(12):1491-1503. PubMed ID: 25306501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant contribution of TRPC6 channel-mediated Ca
    Kurahara LH; Hiraishi K; Sumiyoshi M; Doi M; Hu Y; Aoyagi K; Jian Y; Inoue R
    J Smooth Muscle Res; 2016; 52(0):78-92. PubMed ID: 27818466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model.
    Johnson LA; Rodansky ES; Tran A; Collins SG; Eaton KA; Malamet B; Steiner CA; Huang S; Spence JR; Higgins PDR
    Inflamm Bowel Dis; 2022 Feb; 28(2):161-175. PubMed ID: 34302470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AXL Is a Potential Target for the Treatment of Intestinal Fibrosis.
    Steiner CA; Rodansky ES; Johnson LA; Berinstein JA; Cushing KC; Huang S; Spence JR; Higgins PDR
    Inflamm Bowel Dis; 2021 Feb; 27(3):303-316. PubMed ID: 32676663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can we influence fibrosis in Crohn's disease?
    Assche GV
    Acta Gastroenterol Belg; 2001; 64(2):193-6. PubMed ID: 11475134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisiting fibrosis in inflammatory bowel disease: the gut thickens.
    D'Alessio S; Ungaro F; Noviello D; Lovisa S; Peyrin-Biroulet L; Danese S
    Nat Rev Gastroenterol Hepatol; 2022 Mar; 19(3):169-184. PubMed ID: 34876680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.
    Li C; Kuemmerle JF
    Inflamm Bowel Dis; 2014 Jul; 20(7):1250-8. PubMed ID: 24831560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory bowel disease-associated intestinal fibrosis.
    Park JM; Kim J; Lee YJ; Bae SU; Lee HW
    J Pathol Transl Med; 2023 Jan; 57(1):60-66. PubMed ID: 36623814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TAK1 is a key modulator of the profibrogenic phenotype of human ileal myofibroblasts in Crohn's disease.
    Grillo AR; Scarpa M; D'Incà R; Brun P; Scarpa M; Porzionato A; De Caro R; Martines D; Buda A; Angriman I; Palù G; Sturniolo GC; Castagliuolo I
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(6):G443-54. PubMed ID: 26185333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn's Disease.
    Ueno A; Jijon HB; Peng R; Sparksman S; Mainoli B; Filyk A; Li Y; Wilson S; Novak K; Panaccione R; Hirota S; Dufour A; Lu C; Beck PL
    Inflamm Bowel Dis; 2022 Feb; 28(2):246-258. PubMed ID: 34428284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.